Abstract: A covalent organic framework and a method of preparing the same are disclosed. The covalent organic framework is used to produce an electrode material and includes a repeating unit represented by the following chemical formula: In the formula, A1, A2, and A3 are the same or different, and are independently a monocyclic or polycyclic aromatic ring, and R1 and R2 are the same or different, and are independently selected from hydrogen, a functional group containing at least one nitrogen, phosphorus, or sulfur, an unsubstituted or substituted C1-C6 alkyl group, an unsubstituted or substituted C2-C6 alkenyl group, an unsubstituted or substituted C2-C6 alkynyl group, and an unsubstituted or substituted C1-C6 alkoxy group.

Abstract: A comonomer comprising: wherein W is selected from the group consisting of: S, Se, O, and N-Q; and Q is selected from the group consisting of: a straight-chain or branched carbyl, silyl, or hydrocarbyl, a branched or cyclic alkyl with 1 to 30 atoms, a fused substituted aromatic ring, and a fused unsubstituted aromatic ring. In this comonomer, A and B are independently selected from the group consisting of: H, Br, an aryl group, and a heteroaryl group.

Abstract: The present invention relates to azo dye of formula I defined in claim 1, to a liquid crystalline medium comprising said azo dye, the use of said medium for optical, electrooptical and electronic purposes, in particular in devices for regulating the passage of energy from an outside space into an inside space, for example in windows. The invention further relates to a device containing the liquid crystalline medium according to the invention.

Abstract: A polymer comprising wherein Ar1 and Ar2 are optional and either the same or different and independently selected from an aryl group or an heteroaryl group. In this polymer, W is selected from the group consisting of: S, Se, O, and N-Q; and Q is selected from the group consisting of: a straight-chain or branched carbyl, silyl, or hydrocarbyl, a branched or cyclic alkyl with 1 to 30 atoms, a fused substituted aromatic ring, and a fused unsubstituted aromatic ring. Additionally, in the polymer, R4 and R5 are selected from the group consisting of: a straight-chain or branched carbyl, silyl, or hydrocarbyl, a branched or cyclic alkyl with 1 to 30 atoms, a fused substituted aromatic ring, and a fused unsubstituted aromatic ring; and x+y=1.

Abstract: Disubstituted diaryloxybenzoheterodiazole compound having general formula (I) or (II) and luminescent solar concentrator (LSC) including the same: wherein: Z represents a sulfur atom, an oxygen atom, a selenium atom; or an NR6 group wherein R6 is selected from linear or branched C1-C20 alkyl groups, or from optionally substituted aryl groups; R1, R2 and R3, identical or different, represent a hydrogen atom; or are selected from linear or branched C1-C20 alkyl groups optionally containing heteroatoms, optionally substituted cycloalkyl groups, optionally substituted aryl groups, optionally substituted linear or branched C1-C20 alkoxy groups, optionally substituted phenoxy groups, or a cyano group; or R1 and R2, may optionally be bound together to form, together with the carbon atoms to which they are bound, a saturated, unsaturated or aromatic, cyclic or polycyclic system containing from 3 to 14 carbon atoms, optionally containing one or more heteroatoms; or R2 and R3, may optionally be bound together so

Abstract: Disubstituted diaryloxybenzoheterodiazole compound of general formula (1): in which:—Z represents a sulfur atom, an oxygen atom, a selenium atom; or an NR5 group in which R5 is selected from linear or branched C1-C20, preferably C1-C8, alkyl groups, or from optionally substituted aryl groups;—R1, R2 and R3 are as defined in the claims. The said disubstituted diaryloxybenzoheterodiazole compound of general formula (I) can advantageously be used as a spectrum converter in luminescent solar concentrators (LSCs) which are in turn capable of improving the performance of photovoltaic devices (or solar devices) selected, for example, from photovoltaic cells (or solar cells), photovoltaic modules (or solar modules) on either a rigid substrate or a flexible substrate.

Abstract: The present specification relates to a compound containing nitrogen, and a color conversion film, a backlight unit, and a display device, including the same.

Abstract: The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases.

Abstract: The present application relates to novel compounds and to devices which contain these compounds. The application also relates to a device for regulating the passage of energy from an outside space into an inside space, to a window containing the said device, and to uses of the said devices and compounds.

Abstract: The present invention relates to new semiconducting compounds having at least one optionally substituted thienothiadiazole moiety. The compounds disclosed herein can exhibit high carrier mobility and/or efficient light absorption/emission characteristics, and can possess certain processing advantages such as solution-processability and/or good stability at ambient conditions.

Abstract: The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases.

Abstract: The present invention relates to a method for detecting and optionally quantifying at least one molecule comprising at least one protonated group such as an amine function immobilized at the surface of the solid substrate, said method being a reversible, direct and colorimetric method that uses a coloring agent. The present invention also relates to various uses of said method and the solutions used during said method.

Abstract: The invention relates to suifin- and sulfonimidoylbenzamides of general formula (S) used as herbizides. In said formula (I), R, R?, R?, X, W and Z represent radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogens. Q represents a tetrazolyl-, triazolyl or oxadiazolyl radicals.

Abstract: The present invention relates to an organic colorant corresponding to one of the following structures (I) or (II): eD-pi-conjugated chromophore-L-A??(I) A-L-pi-conjugated chromophore-eD??(II) in which eD represents an electron donor segment; L represents a covalent bond or a spacer segment; A represents an electron attractor segment able to form a covalent bond with a semi-conductor; the pi-conjugated chromophore comprising at least two aromatic rings, at least one of which is a thiophene, selenophene or furan type ring. The present invention relates to the use thereof as photosensitizer in a photovoltaic device and said photovoltaic device.

Abstract: Provided herein are methods and compositions inter alia for treating diseases, including hyperproliferative diseases, migraine headaches, and depression.

Abstract: The present invention relates to novel 1,2,3-triazolyl purine derivatives. The invention also relates to using the derivatives to treat cancer and various viral infections.

Abstract: N-(1,2,5-Oxadiazol-3-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)bicycloarylcarboxamides of the general formula (I) are described as herbicides. In this formula (I), R3, R4 and R5 are each radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogen. Q is a heterocycle. X and Y are each oxygen and sulfur.

Abstract: The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.

Abstract: The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

Abstract: A naphthobisthiadiazole derivative is represented by Formula 1. In Formula 1, Z is selected from a hydrogen atom, a boronic acid group, a boronic acid ester group, a trifluoroborate salt group and a triolborate salt group, and at least one Z is a boronic acid group, a boronic acid ester group, a trifluoroborate salt group or a triolborate salt group. The naphthobisthiadiazole derivative is an organoboron compound, and can be converted to various compounds by a Suzuki-Miyaura coupling reaction; thus, is applicable as a precursor of complex compounds. Using the naphthobisthiadiazole derivative, research, development, and practical applications of low molecular weight compounds and high-molecular compounds useful for various organic semiconductor materials and the like can be ensured.

Abstract: The invention relates to compounds based on benzo[1,2-b:4,5-b?]dithiophene (BDT), methods for their preparation and intermediates used therein, mixtures and formulations containing them, the use of the compounds, mixtures and formulations as semiconductor in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE devices comprising these compounds, mixtures or formulations.

Abstract: The invention provides for novel lipase inhibitors, and compositions and devices comprising the same. The invention further provides for methods for treatment of disorders comprising administration of novel diacylglycerol lipase inhibitors, and compositions and devices comprising said inhibitors. In some embodiments, the disorders are pancreatitis, obesity, shock or pancreatic necrosis. The invention further provides for novel ether lipid reporter compounds and methods of assaying enzymatic activity comprising contacting a compound with a novel ether lipid reporter compound.

Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R0, R1, R2, R3, R4 and a are defined herein.

Abstract: The present invention is directed to novel amino-substituted seven-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Abstract: A benzobis(thiadiazole) derivative represented by the formula (1): in which R represents a group containing at least one fluorine atom (with the proviso that fluorine atom (F) and trifluoromethyl group (—CF3) are excluded), and m represents an integer of from 1 to 10.

Abstract: The present invention relates to 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Abstract: [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.

Abstract: A batch reactor process for the synthesis of potassium 5,7-dinitro-[2,1,3]-benzoxadiazol-4-olate-3-oxide (KDNP) from 3-bromo-2,4,6-trinitroanisole (ETNA) includes adding BTNA to a reaction vessel containing potassium azide (KN3) and water (H2O). The resulting mixture is heated to 90° C. followed by cooling to room temperature and agitating the final solution. The precipitate KDNP product is recovered by filtration.

Abstract: Compound comprising a benzoetherodiazole group of formula (I) and at least one benzodithiophene group or a mixture of compounds comprising a benzoetherodiazole group and at least one benzodithiophene group of formulae (II) and (III). Both said compound and said mixture of compounds can be advantageously used as spectrum converters in luminescent solar concentrators (LSCs), capable, in their turn, of enhancing the performances of solar devices (i.e. devices for exploiting solar energy) such as, for example, photovoltaic cells, photoelectrolytic cells.

Abstract: Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R1, R2, R3, R4, R5, R6, X1 and X2 is as defined in the description. These compounds are protein kinases inhibitors, especially the inhibitors of Mek, which are useful in the treatment of cancers and inflammation of mammals. Disclosed are the treatment methods of cancers and inflammation of mammals as well as pharmaceutical compositions comprising the compounds described herein. The preparation of benzoheterocyclic compounds are disclosed. Disclosed are the preparation of potential drug candidates, such as benzooxazol, benzothiazol, benzothiadiazol and the like.

Abstract: The present invention relates to condensed aromatic compounds with multiple ring bridging of the general formulae (1), (2), (3), (4) and (5). The invention furthermore relates to the use of the compounds according to the invention in an organic electronic device and to a process for the preparation of the compounds according to the invention. The invention furthermore relates to an electronic device which comprises the compounds according to the invention.

Abstract: Thiophene containing water-soluble oligomers were synthesized and characterized. The photophysical properties of these compounds were studied; transient absorption spectroscopy was used to probe the triplet excited state and their ability to sensitize singlet oxygen was spectroscopically monitored in deuterated methanol. The above compounds were tested for their light activated biocidal properties against S. aureus both under UV and visible radiation. Among the oligomers studied, the terthiophene derivative was found to kill the bacteria efficiently.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

Abstract: A photovoltaic cell is provided that includes a first electrode, a second electrode, and a photoactive layer disposed between the first and second electrodes. The photoactive layer includes a photoactive polymer containing a first monomer repeat unit, which contains a moiety of formula (1): in which A and R are defined in the specification.

Abstract: A measure for selective fluorescent labeling of the Golgi apparatus, which has low cytotoxicity and excellent intracellular stability, is provided. According to the present invention, provided are a ceramide derivative represented by the following Chemical formula 1: in the formula, R1 is an alkyl group having 1 to 12 carbon atoms, R2 is an alkyl group having 1 to 20 carbon atoms, and n is an integer of 1 to 20, and a Golgi apparatus-labeling fluorescent probe using the same.

Abstract: A heterocyclic fused anthraquinone derivative, which is represented by a formula (I): wherein R1 is a substituent being one selected from a group consisting of hydrogen, halogens, aminoalkyl group, sulfoalkyl group, haloalkyl group, piperazino group, sulfonyl group, morpholino group, alkali group or one substituent represented by a formula (II): wherein R2 is amino group, oxyl group or a thiol group. In the meantime, a method for manufacturing the above-mentioned heterocyclic fused anthraquinone derivatives and a pharmaceutical composition using thereof are also disclosed here.

Abstract: The presently disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also provided are methods for using the disclosed compositions for diagnosing (i.e., by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activity.

Abstract: Disubstituted naphthoheterodiazole compound having general formula (I): wherein: Z represents a heteroatom selected from oxygen (O), sulfur (S), selenium (Se), tellurium (Te), preferably sulfur (S); R1, R2, R3, R4, R5, R6 and R7, equal to or different from each other, represent a hydrogen atom; or they are selected from n-butyl, iso-butyl, sec-butyl, t-butyl. Said disubstituted naphthoheterodiazole compound having general formula (I) can be advantageously used as spectrum converter in luminescent solar concentrators (LSCs), in its turn capable of improving the performances of photovoltaic devices (or solar devices) selected, for example, from photovoltaic cells (or solar cells), photovoltaic modules (or solar modules), on both rigid and flexible supports.

Abstract: Process for the preparation of a benzoheterodiazole compound disubstituted with benzodithiophene groups which comprises reacting at least one disubstituted benzoheterodiazole compound with at least one monostannylated benzodithiophene compound. Said benzoheterodiazole compound disubstituted with benzodithiophene groups can be advantageously used in the construction of luminescent solar concentrators (LSCs). Furthermore, said benzoheterodiazole compound disubstituted with benzodithiophene groups can be advantageously used in the construction of photovoltaic devices (or solar devices) such as, for example, photovoltaic cells (or solar cells), photovoltaic modules (or solar modules), on both rigid and flexible supports. Furthermore, said benzoheterodiazole compound disubstituted with benzodithiophene groups can be advantageously used as precursor of monomeric units in the preparation of semiconductor polymers.

Abstract: A compound of formula (I): wherein A1, A2, A3, A4, A5, G1, R1, R2, R3 and R4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode and mollusc pests.

Abstract: The present invention relates to compounds with a benzoxadiazolyl amine structure which are capable of inhibiting the activation or the biological activity of p38 mitogen-activated protein kinase (MAPK) and the use thereof in the treatment of a disease that can be alleviated by means of inhibiting the activation or the biological activity of said p38 MAPK, for example, an inflammatory disease or a disease presenting with pain.

Abstract: The present invention relates compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell. The compounds exhibit increased inhibitory activity against c-Myc relative to the known c-Myc inhibitor small-molecule benzofurazan N-([1,1?-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine (10074-G5).

Abstract: The present invention relates to an organic colorant corresponding to one of the following structures (I) or (II): eD-pi-conjugated chromophore-L-A??(I) A-L-pi-conjugated chromophore-eD??(II) in which eD represents an electron donor segment; L represents a covalent bond or a spacer segment; A represents an electron attractor segment able to form a covalent bond with a semi-conductor; the pi-conjugated chromophore comprising at least two aromatic rings, at least one of which is a thiophene, selenophene or furan type ring. The present invention relates to the use thereof as photosensitizer in a photovoltaic device and said photovoltaic device.

Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.

Abstract: Luminescent solar concentrator (LSC) includes at least one disubstituted benzothiadiazole compound having general formula (I):

Abstract: This invention provides compounds of formula (I): wherein ring A, X1, X2, X3, R2, R4b, R10, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

Abstract: Disclosed is a p-type organic semiconductive material that is easy to produce and that has a high planarity in its polymer skeleton, and also provides a photoelectric conversion material, a photoelectric conversion layer, a photoelectric conversion element, and an organic thin film solar cell each having high photoelectric conversion efficiency and using the p-type organic semiconductive material. Specifically, the invention provides a bibenzo[b]furan compound having at least one constitutional unit represented by the following formula (1) or (2), as well as a photoelectric conversion material, a photoelectric conversion layer, a photoelectric conversion element, and an organic thin film solar cell each using that compound for a p-type organic semiconductive material.

Abstract: The present invention relates to 2-oxo-1-pyrrolidine imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Abstract: The present invention provides biaryl oxyacetic acid compounds which may be useful for treating inflammatory disorders, including disorders affecting the respiratory system and skin.